Methotrexate Accord

Methotrexate, the active ingredient in Methotrexate Accord, is an antimetabolite presented as a sterile injectable solution for intra‑arterial, intramuscular and intravenous use. It is employed to treat certain autoimmune disorders and several types of cancer in adult and pediatric patients. GNH USA supplies Methotrexate Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Methotrexate is used across a range of autoimmune and oncologic conditions, acting by inhibiting cell proliferation. - Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: diminishes skin plaque formation and severity. - Acute lymphoblastic leukemia: induces remission by targeting rapidly dividing lymphoblasts. - Non‑Hodgkin lymphoma: impedes tumor growth through DNA synthesis inhibition. - Gestational trophoblastic disease: promotes resolution of abnormal trophoblastic tissue.

Methotrexate may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea and vomiting - Fatigue or weakness - Mucositis (mouth sores) - Alopecia (hair loss) - Elevated liver enzymes - Mild rash

Serious or Rare Side Effects: - Bone marrow suppression leading to pancytopenia - Pulmonary toxicity (interstitial pneumonitis) - Severe hepatotoxicity or fibrosis - Acute renal failure - Life‑threatening cutaneous reactions (e.g., Stevens‑Johnson syndrome) - Severe infection due to immunosuppression

Methotrexate requires careful monitoring and specific safety measures. - Pregnancy: contraindicated (Category X); avoid use in pregnant patients. - Renal function: assess baseline and monitor; adjust or discontinue if impaired. - Liver function: regularly check transaminases; discontinue if significant elevation occurs. - Hematologic monitoring: perform frequent blood counts to detect bone‑marrow suppression. - Drug interactions: review concomitant medications for potential additive toxicity. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate interacts with several drug classes, requiring vigilance.

Major Interactions (Avoid): - NSAIDs: increase risk of renal toxicity. - Penicillins (e.g., ampicillin): may reduce methotrexate clearance. - Proton pump inhibitors: can raise methotrexate plasma levels. - Live vaccines: heightened risk of severe infection.

Moderate Interactions (Monitor Closely): - Sulfonamides: may augment toxicity. - Trimethoprim: potentiates myelosuppression. - Azathioprine: additive bone‑marrow suppression risk.